Blog | BioInformant

RoosterBio and Tissue Regeneration Therapeutics Collaborate on Human Umbilical Cord-Derived MSC Bioprocess Systems

June 9, 2019 By Cade Hildreth, Founder & President Leave a Comment

Collaboration commercializes biological tools to advance the companies’ shared goal of accelerating the field of Regenerative Medicine.

FREDERICK, Md., May 29, 2019 — RoosterBio Inc. and Tissue Regeneration Therapeutics Inc.(TRT) today announced a strategic collaboration to advance their shared goal of accelerating the development of the Regenerative Medicine field. This collaboration will productize TRT’s core technology around human umbilical cord-derived mesenchymal stem/stromal cells (hUC-MSCs) to the entire Regenerative Medicine marketplace. This powerful set of biological tools will be made commercially available via integration into RoosterBio’s unique product formats for rapid incorporation into tomorrow’s Regenerative Medicine products. [Read more…]

Minerva Biotechnologies, Interview with CEO Dr. Cynthia Bamdad

June 4, 2019 By Cade Hildreth, Founder & President 1 Comment

Minerva Biotechnologies is a regenerative medicine company specializing in stem cell therapeutics that is developing cancer immunotherapies to target 75% of solid tumors and to prevent cancer metastasis. I had the honor of interviewing Cynthia Bamdad, PhD, CEO of Minerva Biotechnologies.

In this interview, we discuss Minerva’s technology platform, product portfolio, IP strategy, and strategic goals. We also explore the significance of the company’s AlphaSTEM™ Culture System that is a simple method for inducing the naïve state in human stem cells. Enjoy. [Read more…]

ExCellThera enters into a manufacturing and collaboration agreement with New York Blood Center

June 4, 2019 By Cade Hildreth, Founder & President Leave a Comment

MONTREAL, MAY 7, 2019 – ExCellThera Inc., an advanced clinical stage biotechnology company delivering molecules and bioengineering solutions to expand stem and immune cells for therapeutic use, announced today that it has entered into a manufacturing and collaboration agreement with Comprehensive Cell Solutions (CCS), a division of New York Blood Center (NYBC) for the clinical grade production of ExCellThera’s lead cell therapy product, ECT-001. [Read more…]

ElevateBio to Create a Portfolio of Innovative Cell and Gene Therapy Companies

May 26, 2019 By Cade Hildreth, Founder & President Leave a Comment

– ElevateBio to leverage its fully integrated, company building bench-to-bedside capabilities exclusively focused on cell and gene therapies

– ElevateBio’s BaseCamp, an R&D, process development and cGMP manufacturing subsidiary, provides cell and gene expertise for all ElevateBio portfolio companies and selected strategic partners

– $150 MM Series A financing co-led by UBS Oncology Impact Fund Managed by MPM Capital and F2 Ventures joined by EcoR1 Capital, Redmile Group, and Samsara BioCapital

CAMBRIDGE, Mass. — ElevateBio, a Cambridge-based biotechnology holding company, today announced operations to create and build a broad portfolio of cell and gene therapy companies through partnerships with leading academic researchers, medical centers and entrepreneurs. [Read more…]

Dr. Joseph Purita Receives “Stem Cell Scientist Physician Award”

May 7, 2019 By Cade Hildreth, Founder & President Leave a Comment

Dr. Joseph Purita receives prestigious AAOSCP award for noteworthy contributions to stem cell science and medicine.

The American Academy of Stem Cell Physicians (AAOSCP) is honored to announce that Dr. Joseph Purita, a pioneer in the use of Stem Cell and PRP therapy for orthopedic conditions, has been awarded the prestigious “Stem Cell Scientist Physician Award.” Dr. Purita received this honor at the AAOSCP’s recent Scientific Congress and Workshop at the Mandarin Oriental in Miami, Florida, held over May 3-5, 2019. The event featured 40+ world-class speakers, integrated the use of live patients, and included three days of interactive workshops with small participant-to-instructor ratios. [Read more…]